关于上海盟科药业股份有限公司 中国国际金融股份有限公司 继续使用闲置募集资金进行现金管理的核查意见 中国国际金融股份有限公司（以下简称"中金公司"或"保荐机构"）作为上海盟 科药业股份有限公司（以下简称"盟科药业"或"公司"）首次公开发行股票并在科创 板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《上市公司募集资金监管 规则》《上海证券交易所科创板股票上市规则（2025 年 4 月修订）》《上海证券交易所科 创板上市公司自律监管指引第 1 号——规范运作》等法律、行政法规、部门规章及业务 规则，对盟科药业使用部分暂时闲置募集资金进行现金管理的事项进行了审慎核查，具 体情况如下： 一、盟科药业募集资金基本情况 经中国证券监督管理委员会出具的《关于同意上海盟科药业股份有限公司首次公开 发行股票注册的批复》（证监许可[2022]1204 号）同意，公司首次公开发行的人民币普 通股（A 股）13,000.00 万股（每股面值人民币 1.00 元），发行价格为 8.16 元/股，本次 发行募集资金总额为 106,080.00 万元，扣除各项发行费用（不含增值税）人民币 10,107.21 万元后，实际募集资金净 ...

证券代码：688373 证券简称：盟科药业 公告编号：2025-028 上海盟科药业股份有限公司 关于继续使用闲置募集资金进行现金管理的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海盟科药业股份有限公司（以下简称"公司"）于 2025 年 8 月 5 日召开第 二届董事会第十七次会议、第二届监事会第十二次会议，审议通过了《关于继续 使用闲置募集资金进行现金管理的议案》，同意公司在确保不影响募集资金投资 项目实施及募集资金安全的前提下，使用最高不超过 5 亿元（含本数）的暂时闲 置募集资金进行现金管理，购买投资如结构性存款、大额存单等安全性高、流动 性好的保本型产品，单笔最长期限不超过 12 个月，使用期限自公司董事会审议 通过之日起 12 个月之内有效。在前述额度及期限范围内，公司可以循环滚动使 用。 公司董事会授权公司管理层办理闲置募集资金购买投资产品相关事宜，具体 事项由公司财务部负责组织实施。上述事项在公司董事会审批权限范围内，无需 提交公司股东大会审议。公司监事会发表了明确同意的意见，保荐机构中国国际 ...

Group 1 - The company, Amgen Pharmaceutical (688373.SH), plans to continue using up to RMB 500 million of temporarily idle raised funds for cash management [1] - The maximum duration for each transaction will not exceed 12 months, effective from the date of approval by the company's board of directors [1] - Within the specified limit and validity period, the funds can be used in a rolling manner [1]

| 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 弘业期货 | 001236 | 发行前股份限售流通 | 4.32亿 | | 江波龙 | 301308 | 发行前股份限售流通 | 3亿 | | 广立微 | 301095 | 发行前股份限售流通 | 7592.2万 | | 中微半导 | 688380 | | 2128.5万 | | 盟科药业 | 688373 | | 2.83亿 | 今日具体限售解禁股情况如下： 智通财经APP获悉，8月5日共有5家上市公司的限售股解禁，解禁总市值约382.85亿元。 ...

Core Insights - The report highlights the significant role of company secretaries (董秘) in connecting investors and listed companies, with a total salary of 4.086 billion yuan for A-share company secretaries in 2024, averaging 754,300 yuan per year [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] Age Distribution - The age distribution of company secretaries indicates that 47% are between 40-50 years old, 23% are over 50, 29% are between 30-40, and only 1% are under 30, with the youngest being 28 years old [1] Educational Background - The educational background of company secretaries shows that 4% have an associate degree, 42% hold a bachelor's degree, 50% have a master's degree, and 4% possess a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings per year, while only 1% have more than 1,000 meetings [9] Top Earning Company Secretaries - The top five highest-paid company secretaries have salaries ranging from 325.65 million yuan to 738.76 million yuan, with the youngest among them being 32 years old and having just started in the role [7]

Core Insights - The report highlights that the total salary of A-share listed company secretaries reached 4.086 billion yuan in 2024, with an average annual salary of 754,300 yuan [1] - Over 21% of the secretaries earn more than 1 million yuan annually, indicating a significant compensation level in the industry [1] Salary Distribution - The salary distribution among secretaries in the biopharmaceutical sector shows that 32% earn below 500,000 yuan, 41% earn between 500,000 and 1 million yuan, 23% earn between 1 million and 2 million yuan, 3% earn between 2 million and 3 million yuan, and 1% earn above 3 million yuan [5] - Five secretaries with salaries exceeding 3 million yuan include Li Wenmei from Mindray Medical (7.3876 million yuan), Jiang Yueheng from Yifang Bio (5.2065 million yuan), and others, with the youngest being 32 years old [7] Age and Educational Background - The age distribution of secretaries shows that those aged 40-50 constitute 47%, while those over 50 account for 23%, and those aged 30-40 make up 29%. Secretaries under 30 represent 1% [1] - In terms of educational qualifications, 4% have an associate degree, 42% hold a bachelor's degree, 50% possess a master's degree, and 4% have a doctoral degree, with over half holding a master's degree or higher [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 32% of companies hosting fewer than 10 meetings annually, while only 1% have more than 1,000 meetings [9] - The top five companies with the most investor meetings include Sanofi Biologics and others, with meeting counts ranging from 1,107 to 2,661 [10]

Core Insights - The report highlights that in 2024, the total salary of A-share listed company secretaries reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - A total of 1,144 company secretaries earned over 1 million yuan annually, accounting for more than 21% of the total [1] Salary Distribution - The salary distribution for company secretaries in the A-share biopharmaceutical sector is as follows: - Below 500,000 yuan: 153 individuals (32%) - 500,000 to 1 million yuan: 199 individuals (41%) - 1 million to 2 million yuan: 114 individuals (23%) - 2 million to 3 million yuan: 16 individuals (3%) - Over 3 million yuan: 5 individuals (1%) [5] Age Distribution - The age distribution of company secretaries shows that: - Ages 40-50: 47% - Ages 50 and above: 23% - Ages 30-40: 29% - Under 30: 1%, with the youngest being 28 years old [1] Educational Background - The educational qualifications of company secretaries are as follows: - Associate degree: 4% - Bachelor's degree: 42% - Master's degree: 50% - Doctorate: 4% - More than half of the company secretaries hold a master's degree or higher [3] Investor Engagement - The frequency of investor engagements varies significantly among companies: - Less than 10 times: 129 companies (32%) - 10 to 100 times: 149 companies (37%) - 100 to 300 times: 79 companies (20%) - 300 to 1000 times: 42 companies (10%) - More than 1000 times: 5 companies (1%) [7] Top Investor Engagement Companies - The companies with the highest number of investor engagements are: - Sanofi Biologics: 2,661 times - Bohui Innovation: 1,500 times - Zexin Pharmaceutical: 1,418 times - Aibo Medical: 1,263 times - Kangtai Medical: 1,107 times [9]

Core Viewpoint - The report outlines the verification opinions of China International Capital Corporation regarding the lifting of restrictions on the circulation of part of the restricted shares of Shanghai Mengke Pharmaceutical Co., Ltd. The restricted shares will be available for trading on August 5, 2025, involving a total of 159,444,366 shares, which accounts for 24.32% of the company's total share capital [1][3][8]. Group 1: Restricted Shares Details - The total number of shares after the initial public offering (IPO) is 655,210,084, with 118,687,659 shares being unrestricted and 536,522,425 shares being restricted [2]. - The restricted shares involved in this circulation are from five shareholders, with a lock-up period of 36 months from the date of the company's stock listing [3]. - The total number of restricted shares to be listed for circulation is 159,444,366, which will be available for trading on August 5, 2025 [4][6]. Group 2: Share Capital Changes - Following the implementation of the 2023 restricted stock incentive plan, the company's total share capital increased from 655,210,084 shares to 655,605,491 shares [3]. - The increase in share capital is attributed to the vesting of restricted stocks under the incentive plan [3]. Group 3: Shareholder Commitments - Shareholders have made commitments regarding the locked shares, including not transferring or proposing to repurchase the shares during the lock-up period of 36 months [5][6]. - After the lock-up period, shareholders plan to reduce their holdings in compliance with relevant laws and regulations, ensuring that the selling price will not be lower than the IPO price adjusted for any corporate actions [5][6]. Group 4: Verification Opinions - The sponsor institution, China International Capital Corporation, has verified that the application for the lifting of restrictions on the shares complies with relevant laws and regulations, and the shareholders have adhered to their commitments made during the IPO [7][8].

Core Viewpoint - Shanghai Mengke Pharmaceutical Co., Ltd. is set to list 159,444,366 restricted shares for trading on August 5, 2025, following its initial public offering (IPO) [1][3][6] Group 1: Listing Details - The total number of shares for this listing is 159,444,366, which are part of the restricted shares from the company's IPO [1][6] - The shares will be available for trading starting on August 5, 2025 [1][6] - The company received approval from the China Securities Regulatory Commission for the public offering of 13 million shares, which were listed on August 5, 2022 [1][3] Group 2: Shareholder Information - The restricted shares involve five shareholders: MicuRx(HK) Limited, Best Idea International Limited, JSR Limited, GP TMT Holdings Limited, and Xinyi Youmaikos Financial Consulting Center (Limited Partnership) [3][6] - The restricted period for these shares is 36 months from the date of the company's stock listing [3][4] Group 3: Changes in Share Capital - Following the implementation of the 2023 restricted stock incentive plan, the company's total share capital increased from 655,210,084 shares to 655,605,491 shares [2][3] - The increase in share capital is attributed to the vesting of restricted stocks under the incentive plan [2][3] Group 4: Shareholder Commitments - Shareholders have committed not to transfer or propose the repurchase of their shares during the 36-month lock-up period [4][5] - After the lock-up period, any share reduction must comply with relevant laws and regulations, ensuring that the selling price does not fall below the IPO price adjusted for any corporate actions [4][5] Group 5: Verification by Intermediaries - The sponsoring institution has verified that the application for the listing of restricted shares complies with legal requirements and that shareholders have adhered to their commitments [6]

证券代码：688373 证券简称：盟科药业 公告编号：2025-026 上海盟科药业股份有限公司 首次公开发行部分限售股上市流通公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次股票上市类型为首发限售股份；股票认购方式为网下，上市股数为 159,444,366股。 本次股票上市流通总数为159,444,366股。 本次股票上市流通日期为2025 年 8 月 5 日。 一、本次上市流通的限售股类型 本次上市流通的限售股属于公司首次公开发行部分限售股，共涉及限售股股 东5名（MicuRx(HK) Limited、Best Idea International Limited、JSR Limited、GP TMT Holdings Limited、新沂优迈科斯财务咨询中心（有限合伙）），限售期为自公司 股票上市之日起36个月，共涉及公司159,444,366股股份，占公司总股本比例为 24.32%。 本次上市流通的限售股将于2025年8月5日起上市流通。 二、本次上市流通的限售股形成后至今公司股本数量变化 ...